title: Bacterial translocation-related mortality may be associated with neutrophil-mediated organ damage.
abstract: Balb/c mice were transfused with .2 mL of C3H/HeJ mouse blood. 5 days later, the mice were gavaged with 10(10) 14C-labeled Escherichia coli, and a 20% full thickness flame burn was inflicted. Additional animals were treated with enisoprost (prostaglandin E1 (PGE1) analog) 200 micrograms/kg/day orally for 3 days before burn. Bacterial translocation was determined by both radionuclide counts (dpm) and viable colony counts 24 h post burn. Neutrophil accumulation was evaluated by the measurement of myeloperoxidase (MPO) in the liver. In addition, splenic macrophages were separated and cultured for 24 h with or without 10 micrograms/mL of LPS. Tumor necrosis factor, interleukin-1 (IL-1), IL-6, and PGE2 were measured in the cell culture supernatants. Consistent with previous work, enisoprost significantly reduced translocation. MPO in the liver was significantly greater in the control group compared to the enisoprost group. There was a significant correlation between MPO content and the degree of bacterial translocation (p < .05). Lipopolysaccharide-stimulated macrophage production of IL-1, IL-6, and PGE2 were significantly greater in the enisoprost group.
authors.affiliation: University of Cincinnati Medical Center, Ohio 45267-0558, USA.
authors.forename: R
authors.initials: R
authors.lastname: Fukushima
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: L
authors.initials: L
authors.lastname: Gianotti
authors.forename: T
authors.initials: T
authors.lastname: Pyles
authors.forename: C K
authors.initials: CK
authors.lastname: Ogle
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D018407:Bacterial Physiological Phenomena; D001803:Blood Transfusion; D002056:Burns / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D002634:Chemotaxis, Leukocyte; D015232:Dinoprostone / Q000096:biosynthesis; D004926:Escherichia coli / Q000502:physiology; D005260:Female; D007375:Interleukin-1 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology*; D008099:Liver / Q000473:pathology*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009102:Multiple Organ Failure / Q000382:microbiology / Q000503:physiopathology*; D009504:Neutrophils / Q000502:physiology*; D009195:Peroxidase / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D009195:Peroxidase; D000527:Alprostadil; C054594:enisoprost; D015232:Dinoprostone